Why the study?
The study evaluated the efficiency of combination antihypertensive therapy with valsartan and amlodipine in patients with arterial hypertension and obesity, depending on CYP2C9 and CYP11B2 gene polymorphisms.
Does combination therapy with valsartan and amlodipine improve antihypertensive and vasoprotective efficiency in obese patients with arterial hypertension depending on CYP2C9 and CYP11B2 gene polymorphisms?
Does combination therapy with valsartan and amlodipine improve antihypertensive and vasoprotective efficiency in obese patients with arterial hypertension depending on CYP2C9 and CYP11B2 gene polymorphisms?
Purpose. To evaluate the efficiency of combination antihypertensive therapy with valsartan and amlodipine in patients with arterial hypertension (AH) and obesity, depending on the polymorphisms of the CYP2C9 and CYP11B2 genes. Materials and methods. In research included 80 obese patients (body mass index ≥30 kg/m2) and AH 1-2 disease blood pressure (BP) ≥140/90 mm Hg and
No takes yet. Share an insight, caveat, or question.
Kovalenko et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: